Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc covers the period ending June 22, 2007. The report details a share repurchase transaction executed in accordance with shareholder authority granted at the Annual General Meeting on May 23, 2007.
Key Financial Metrics
The filing does not provide revenue, profit, cash flow, margin, debt, or liquidity figures. It focuses exclusively on capital structure changes related to share buybacks.
- Shares Purchased: 1,260,000 Ordinary shares
- Purchase Price: 1,296.05 pence per share
- Treasury Shares Held: 320,899,158 (representing 5.63% of total voting rights)
- Shares in Issue: 5,699,867,856 (excluding Treasury shares)
Material Changes
The primary material change is the reduction of outstanding shares through the acquisition of 1,260,000 shares on June 22, 2007. These shares are held in Treasury. The filing does not provide comparative data against prior periods for financial performance.
Guidance, Outlook, and Risks
The filing contains no forward-looking guidance, management commentary on operational outlook, or discussion of risks and contingencies. It is a compliance disclosure confirming conformity with the Financial Services Authority's Disclosure and Transparency Rules.
Investor Verification Points
- Verify the total number of shares in issue (5,699,867,856) for calculating ownership thresholds under Disclosure and Transparency Rules.
- Confirm the updated Treasury share count (320,899,158) and its impact on total voting rights (5.63%).
- Note that this announcement does not constitute an offer to purchase or subscribe for securities.